Revolution Medicines yesterday reported unprecedented phase III data for daraxonrasib in second-line PDAC, showing a near doubling of overall survival in patients with pancreatic cancer. The results are widely viewed as practice-changing and position KRAS inhibition as a new backbone in PDAC. We comment on the consequences for Cantargia.
LÄS MER
